S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8+ T Cell‐Mediated Ant...
S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8+ T Cell‐Mediated Anti‐Cancer Immunity in Bladder Carcinoma
About this item
Full title
Author / Creator
Li, Huihuang , Chen, Jinbo , Li, Zhenghao , Chen, Minfeng , Ou, Zhenyu , Mo, Miao , Wang, Ruizhe , Tong, Shiyu , Liu, Peihua , Cai, Zhiyong , Zhang, Chunyu , Liu, Zhi , Deng, Dingshan , Liu, Jinhui , Cheng, Chunliang , Hu, Jiao and Zu, Xiongbing
Publisher
Germany: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Germany: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Although immune checkpoint blockade (ICB) therapies have been approved for bladder cancer (BLCA), only a minority of patients respond to these therapies, and there is an urgent need to explore combined therapies. Systematic multi‐omics analysis identified S100A5 as a novel immunosuppressive target for BLCA. The expression of S100A5 in malignant cel...
Alternative Titles
Full title
S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8+ T Cell‐Mediated Anti‐Cancer Immunity in Bladder Carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_93d943543f234e55a0ab440f97643444
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_93d943543f234e55a0ab440f97643444
Other Identifiers
ISSN
2198-3844
E-ISSN
2198-3844
DOI
10.1002/advs.202300110
